Clinical Trials
7 trialsNCT06997068 2026-05-11
Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States Population
Mayo Clinic
Phase 2 Recruiting
NCT04162873 2025-02-12
Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer
University of Utah
Phase 2 Terminated
NCT00052611 2018-03-29
Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00953849 2017-03-07
Vitamin D Plus Celecoxib Therapy to Stimulate Intratumoral Immune Reactivity
VA Office of Research and Development
Phase 1/2 Completed
NCT00934739 2015-02-25
A Study of High-Risk Oral Cavity Cancer
National Health Research Institutes, Taiwan
Phase 2/3 Terminated
NCT00101335 2013-07-11
Celecoxib in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia
Fox Chase Cancer Center
Phase 2 Completed
NCT00014404 2013-01-16
Celecoxib in Treating Patients With Precancerous Lesions of the Mouth
Memorial Sloan Kettering Cancer Center
Phase 2 Completed